- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01434667
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Study Overview
Status
Conditions
Detailed Description
Alzheimer's disease is a common condition affecting memory and thinking. Genes can sometimes be used to provide risk estimates for the eventual development of certain common diseases. Apolipoprotein E (APOE) is one gene which can provide information about a person's chances of developing Alzheimer's disease.
Some people with a diagnosis of Mild Cognitive Impairment (MCI) are curious to learn more about the chance of developing Alzheimer's disease. In the REVEAL IV Study, we are examining the psychological and behavioral impact of learning genetic risk information pertaining to the chance for an individual with MCI to progress to dementia of the Alzheimer's type within three years.
Participation in this study requires an initial phone call which will elicit some demographic information about the participant and his or her study partner. A first in-person visit to the research clinic will consist of an education session, the administration of knowledge and attitudinal surveys and some tests to assess memory and thinking skills. This visit will take approximately 2-3 hours. Participants with MCI will have their blood drawn for genetic testing. Participants will then be randomized to one of two groups. Those in the intervention arm will receive a three-year risk estimate for the chance of progressing to dementia of the Alzheimer's type based on age, the diagnosis of MCI and their own APOE gene test result. Those in the comparison arm will receive a three-year risk estimate for the chance of progressing to dementia of the Alzheimer's type based on age and the diagnosis of MCI, without the APOE gene test result. Participants randomized to the comparison arm will have the opportunity to learn their own APOE gene test result at the end of the study. Participants and their study partners will be followed for 6 months following disclosure of results with 1 additional clinic visit and 1 additional phone interviews.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20060
- Howard University
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Individuals (55-90 years old) with Mild Cognitive Impairment (amnestic-MCI as defined by the Petersen criteria)
- Individuals who have a close friend, relative or spouse (18+) willing to be a study partner. Study partners attend each study visit with the participant and also complete surveys and interviews.
Exclusion Criteria:
- Individuals with current, untreated anxiety or depression
- Individuals who do not meet the criteria for amnestic-MCI
- Individuals who have the diagnosis of dementia or Alzheimer's disease
- Individuals not fluent in English
- Individuals who do not have a study partner
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: APOE Genotype Non-Disclosure
Subjects will receive Alzheimer's disease risk disclosure.
This assessment is based on age and MCI status alone.
|
Subjects with MCI will learn a three-year numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
|
Experimental: APOE Genotype Disclosure
Subjects will receive both APOE genotype and Alzheimer's disease risk disclosure.
The assessment is based on age, MCI status, and genotype.
|
Subjects with MCI will learn their own APOE genotype and a three-year numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Geriatric Depression Scale
Time Frame: Baseline, 6 weeks post-disclosure, and 6 months post-disclosure
|
A 15-item self-report assessment used to identify depression in the elderly.
GDS scores ranged from 0-15.
Higher scores indicated greater depression.
|
Baseline, 6 weeks post-disclosure, and 6 months post-disclosure
|
Mini State Trait Anxiety Inventory
Time Frame: Baseline, 6 weeks post-disclosure, and 6 months post-disclosure
|
Validated introspective psychological inventory consisting of 6 self-report items pertaining to anxiety affect.
Responses are transformed into scores that range from 20 to 80, with higher scores indicating greater anxiety.
|
Baseline, 6 weeks post-disclosure, and 6 months post-disclosure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Impact of Event Scale (IES)
Time Frame: 1-3 Days, 6 Weeks and 6 Months Post-disclosure
|
The Impact of Event assesses intrusive thoughts and avoidance related to a specific stressful life event.
It is a 15-item self-report measure with scores that range from 0 to 75, with greater scores indicating greater distress about the event.
|
1-3 Days, 6 Weeks and 6 Months Post-disclosure
|
Psychological Impact of Test Disclosure (IGT-AD)
Time Frame: 6 Weeks and 6 Months Post-disclosure
|
A 15-item scale measuring distress specific to the test results received.
Scores range from 0-75, with higher scores indicating greater test-related distress.
Higher scores indicate greater distress about the risk assessment.
|
6 Weeks and 6 Months Post-disclosure
|
Recall and Comprehension of Risk Information
Time Frame: 6 Weeks and 6 Months Post-disclosure
|
Several measures to assess participant recall and comprehension of personalized risk information for AD.
The sum number correct of the two items that were presented to both randomization arms ("What form of APOE increases risk for Alzheimer's disease?", and "What percentage were you given as your 3-year risk of developing Alzheimer's disease?") are summarized here.
|
6 Weeks and 6 Months Post-disclosure
|
Participant Satisfaction
Time Frame: 6 Weeks and 6 Months Post-disclosure
|
How well participants' expectations about information, explanations, reassurance, advice, and help in decision making were met.
Participants rated satisfaction for each dimension on a 1-7 scale, with higher scores indicating that expectations were met better.
|
6 Weeks and 6 Months Post-disclosure
|
User Ratings of Risk Assessment Experience
Time Frame: 6 Weeks and 6 Months Post-disclosure
|
Subjective ratings of the impact of risk assessment.
Participants provided ratings on a 1-5 scale, with 1 being "very negative" and 5 being "very positive"
|
6 Weeks and 6 Months Post-disclosure
|
Health Behavior and Insurance Changes
Time Frame: Baseline, 6 weeks post-disclosure, and 6 months post-disclosure
|
AD prevention behaviors enacted within the prior two weeks.
|
Baseline, 6 weeks post-disclosure, and 6 months post-disclosure
|
Insurance and Advance Planning Changes
Time Frame: 6 months post-disclosure
|
A series of yes/no questions that ask whether the risk assessment motivated changes to insurance or advance planning.
|
6 months post-disclosure
|
Participation in Alzheimer's Disease-related Research After Receiving the Alzheimer's Disease Risk Estimate.
Time Frame: 6 weeks and 6 months post-disclosure
|
Yes/no response to the question, "Since receiving your Alzheimer's disease risk estimate, have you joined any other Alzheimer's disease-related research studies?"
|
6 weeks and 6 months post-disclosure
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Robert C Green, MD, MPH, Brigham and Women's Hospital/Harvard Medical School
Publications and helpful links
General Publications
- Roberts JS, Christensen KD, Green RC. Using Alzheimer's disease as a model for genetic risk disclosure: implications for personal genomics. Clin Genet. 2011 Nov;80(5):407-14. doi: 10.1111/j.1399-0004.2011.01739.x. Epub 2011 Jul 18.
- Roberts JS, Karlawish JH, Uhlmann WR, Petersen RC, Green RC. Mild cognitive impairment in clinical care: a survey of American Academy of Neurology members. Neurology. 2010 Aug 3;75(5):425-31. doi: 10.1212/WNL.0b013e3181eb5872.
- Guan Y, Roter DL, Wolff JL, Gitlin LN, Christensen KD, Roberts JS, Green RC, Erby LH. The impact of genetic counselors' use of facilitative strategies on cognitive and emotional processing of genetic risk disclosure for Alzheimer's disease. Patient Educ Couns. 2018 May;101(5):817-823. doi: 10.1016/j.pec.2017.11.019. Epub 2017 Nov 27.
- Guan Y, Roter DL, Erby LH, Wolff JL, Gitlin LN, Roberts JS, Green RC, Christensen KD. Disclosing genetic risk of Alzheimer's disease to cognitively impaired patients and visit companions: Findings from the REVEAL Study. Patient Educ Couns. 2017 May;100(5):927-935. doi: 10.1016/j.pec.2016.12.005. Epub 2016 Dec 14.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R01HG002213 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mild Cognitive Impairment
-
University of California, San FranciscoNational Institute on Aging (NIA)RecruitingMild Cognitive Impairment | Cognitive Decline | Cognitive Deterioration | Cognitive Impairment, Mild | Cognitive Deficits, MildUnited States
-
BaycrestCentre for Aging and Brain Health InnovationUnknownNeurocognitive Disorders | Cognitive Dysfunction | Mental Disorder | Cognitive Impairment, Mild | Cognitive Disorder | Nonamnestic Mild Cognitive ImpairmentCanada
-
Mackay Memorial HospitalBened Biomedical Co., Ltd.RecruitingMild Cognitive Impairment (MCI)Taiwan
-
Thomas Jefferson UniversityJohns Hopkins University; University of Pennsylvania; National Institute on Aging... and other collaboratorsCompletedMild Cognitive Impairment (MCI)United States
-
Palo Alto Veterans Institute for ResearchU.S. Army Medical Research and Development CommandCompletedAmnestic Mild Cognitive ImpairmentUnited States
-
Assaf-Harofeh Medical CenterNeurim Pharmaceuticals Ltd.UnknownMild Cognitive Impairment (MCI)Israel
-
Xuanwu Hospital, BeijingWuhan University; Beijing Friendship Hospital; First Affiliated Hospital Xi'an... and other collaboratorsRecruitingAmnestic Mild Cognitive ImpairmentChina
-
Immunotec Inc.RecruitingMild Cognitive Impairment (MCI)Canada
-
Jennifer BramenNational Institutes of Health (NIH); National Institute on Aging (NIA)CompletedAmnestic Mild Cognitive ImpairmentUnited States
-
Meir Medical CenterTerminatedMild Cognitive Impairment (MCI)Israel
Clinical Trials on Alzheimer's disease risk disclosure
-
Brigham and Women's HospitalBoston University; University of Pennsylvania; University of Michigan; Duke University and other collaboratorsCompletedAlzheimer Disease | Education | Neuroimaging | Risk Assessment | Neuropsychological Tests | Amyloid Beta-PeptidesUnited States
-
Massachusetts General HospitalNational Heart, Lung, and Blood Institute (NHLBI)RecruitingCoronary Artery DiseaseUnited States
-
Vanderbilt University Medical CenterRecruitingAlzheimer Disease | Mild Cognitive ImpairmentUnited States
-
University of MichiganNational Institute on Aging (NIA)CompletedHealthy Aging | Mild Cognitive ImpairmentUnited States
-
University of British ColumbiaHealth Canada; Brain Canada; Michael Smith Foundation for Health Research; Women... and other collaboratorsActive, not recruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive ImpairmentCanada
-
Barcelonabeta Brain Research Center, Pasqual Maragall...CompletedDementia | Alzheimer Disease | Mild Cognitive Impairment | Subjective Cognitive DeclineSpain
-
Umeå UniversityKarolinska Institutet; Lund University; Göteborg UniversityEnrolling by invitationLynch Syndrome | Hereditary Breast and Ovarian Cancer Syndrome | Familial Breast Cancer | Hereditary Breast Cancer | Familial Colorectal CancerSweden
-
Technical University of MunichUniversity of Leipzig; Humboldt-Universität zu Berlin; Zentralinstitut für Seelische...Completed
-
Hospital del Mar Research Institute (IMIM)Enrolling by invitationNeurodegenerative Diseases | Cognitive Impairment | Dementia | Alzheimer Disease | Lewy Body Disease | Frontotemporal Dementia | Vascular DementiaSpain
-
Memorial University of NewfoundlandOcean Frontier InstituteActive, not recruiting